Company / R&D Expense
Exelixis R&D Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$825.0M
FY2025
5-year range
$337.0M / $1.0B
FY2021-FY2025
Trend
-9.4%
vs FY2024
Sector context
#22 of 210
Health Care
What the data says
Among 210 Health Care companies, Exelixis is in the top 10% for r&d expense. R&D Expense has fluctuated over the past 10 years, ranging from $96M in FY2018 to $1.0B in FY2023.
Based on SEC 10-K filings.
$825M in FY2025 with a 5-year CAGR of +8.5%. Top quartile in the Health Care sector.
Declined from $1.0B to $825M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +14.6%
- 5-Year CAGR
- +8.5%
- 10-Year CAGR
- -
Sector benchmark
Top 10% in Health CareTop 10% of 210This company $825.0M Sector average $644.0M
▼
+28.1% above sector average
Key checks
Key Insights
- 5-year CAGR of +8.5%, indicating consistent growth.
- In FY2025, r&d expense decreased 9.4% year-over-year.
- Ranks #22 out of 210 companies in the Health Care sector.
- Peak r&d expense was recorded in FY2023.
Company context
Key Data Points
- Altman Z-Score 3.33 (safe zone, above 2.9 threshold)
- Strong profit margin: 29.6%
- High earnings quality (cash-backed earnings)
- Strong return on equity: 31.4%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $825.0M | -9.4% |
| FY2024 | $910.4M | -12.8% |
| FY2023 | $1.0B | +90.6% |
| FY2022 | $547.9M | +62.6% |
| FY2021 | $337.0M | -38.5% |
| FY2020 | $547.9M | +62.6% |
| FY2019 | $337.0M | +251.1% |
| FY2018 | $96.0M | -14.4% |
| FY2017 | $112.2M | +16.9% |
| FY2016 | $96.0M | -0.4% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026